12
Views
6
CrossRef citations to date
0
Altmetric
Research Article

Overview Cardiovascular & Renal: Angiotensin antagonists: agents that interact with the AT2 receptor and their potential therapeutic utilities

Pages 1325-1338 | Published online: 03 Mar 2008

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

. (1995) Cardiovascular & Renal: AT2 antagonist inhibition of vascular restenosis. Expert Opinion on Therapeutic Patents 5:6, pages 571-572.
Read now

Articles from other publishers (5)

W.J. Greenlee. 1997. Proceedings XIVth International Symposium on Medicinal Chemistry. Proceedings XIVth International Symposium on Medicinal Chemistry 97 107 .
Ruth R. Wexler, William J. Greenlee, John D. Irvin, Michael R. Goldberg, Kristine Prendergast, Ronald D. Smith & Pieter B. M. W. M. Timmermans. (1996) Nonpeptide Angiotensin II Receptor Antagonists:  The Next Generation in Antihypertensive Therapy. Journal of Medicinal Chemistry 39:3, pages 625-656.
Crossref
Pierre Deprez, Jacques Guillaume, Alain Corbier, Jean-Paul Vevert, Michel Fortin & Bertrand Heckmann. (1995) Balanced AT1 and AT2 angiotensin II antagonists. III. potent and orally active 5-β-ketosulfoxide imidazolyl biphenyl sulfonylureas. Bioorganic & Medicinal Chemistry Letters 5:22, pages 2617-2622.
Crossref
Pierre Deprez, Jacques Guillaume, Alain Corbier, Michel Fortin, Jean-Paul Vevert & Bertrand Heckmann. (1995) Balanced AT1 and AT2 angiotensin II antagonists. II. Potent 5 α-hydroxyacid imidazolyl biphenyl sulfonylureas. Bioorganic & Medicinal Chemistry Letters 5:22, pages 2611-2616.
Crossref
Pierre Deprez, Bertrand Heckmann, Alain Corbier, Jean-Paul Vevert, Michel Fortin & Jacques Guillaume. (1995) Balanced AT1 and AT2 angiotensin II antagonists. I. New orally active 5-carboxyl imidazolyl biphenyl sulfonylureas. Bioorganic & Medicinal Chemistry Letters 5:22, pages 2605-2610.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.